Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02030925 · ClinicalTrials.gov registry record · Phase 2
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT02030925 is a Phase 2 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 93 participants.
The verdict
NCT02030925, a Phase 2 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease (GERD).
Interventions
- DRUG Matching Placebo
- DRUG IW-3718
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02030925
The ClinicalTrials.gov registry entry for NCT02030925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02030925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02030925 about?
NCT02030925 is a clinical study titled "Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors". This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease (GERD).
What is the current status of trial NCT02030925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2014-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02030925?
The interventions under investigation include: Matching Placebo (DRUG), IW-3718 (DRUG).
Who is sponsoring clinical trial NCT02030925?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.